



#6 Receipt  
08-20-01

Docket No.: 44041.010400

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In re Patent Application of

Cochrum *et al.*

AUG 17 2001

Serial No.: 09/438,872

Group Art Unit: 1651

TECH CENTER 1600/2900

Filed: November 12, 1999

Examiner: Sandra Saucier

For: Hemostatic Polymer Useful for Rapid Blood Coagulation and Hemostasis

Assistant Commissioner for Patents  
Office of Petitions  
Washington, D.C. 20231

REQUEST FOR CORRECTED FILING RECEIPT

Sir:

Applicants respectfully request that the Commissioner issue a Corrected Filing Receipt in view of one error contained in the Official Filing Receipt mailed on May 18, 2001. A copy of the Official Filing Receipt is attached hereto.


The Group Art Unit should have been correctly listed as 1651 instead of 1615.

Applicants respectfully request that the Commissioner issue a new Corrected Filing Receipt which includes the corrected information as stated above. Please charge any required fee to the Greenberg Traurig Deposit Account No. 501561.


Respectfully Submitted,

Greenberg Traurig, LLP

Date: August 1, 2001

By:   
EUGENE C. RZUCADLO  
Attorney for Applicants  
Registration No. 31,900  
GREENBERG TRAURIG, LLP  
885 Third Avenue, 22nd Floor  
New York, NY 10022-4834  
(212) 801-9200


FILING RECEIPT



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
ASSISTANT SECRETARY AND COMMISSIONER  
OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTORNEY DOCKET NO.	DRWGS	TOT CL	IND CL
09/438,872	11/12/99	1615	\$674.00-49239.5		10	44	5

VINEET KOHLI  
GRAHAM & JAMES LLP  
INTELLECTUAL PROPERTY GROUP  
885 THIRD AVENUE  
NEW YORK NY 10022



Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts of Application" ("Missing Parts Notice") in this application, please submit any corrections to this Filing Receipt with your reply to the "Missing Parts Notice." When the PTO processes the reply to the "Missing Parts Notice," the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s) KENT C. COCHRUM, DAVIS, CA; ROBERT A. GUNTHER, DAVIS, CA; SUSAN A. JEMTRUD, SAN FRANCISCO, CA; FRANKLIN M. BENINSIG, SACRAMENTO, CA.

CONTINUING DATA AS CLAIMED BY APPLICANT-  
PROVISIONAL APPLICATION NO. 60/108,185 11/12/98

IF REQUIRED, FOREIGN FILING LICENSE GRANTED 12/17/99 \*\* SMALL ENTITY \*\*  
TITLE

HEMOSTATIC POLYMER USEFUL FOR RAPID BLOOD COAGULATION AND HEMOSTASIS

PRELIMINARY CLASS: 424

CENSE FOR FOREIGN FILING U. S. PATENT OFFICE  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "FOREIGN FILING LICENSE GRANTED" followed by a date appears on the reverse side of this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.11. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related application(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations, especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR Parts 121-128) ); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j) ); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "FOREIGN FILING LICENSE GRANTED" DOES NOT appear on the reverse side of this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

**PLEASE NOTE ---- The Following Information about the Filing Receipt:**

The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.

The words "new," "improved," "improvement," "improvements in or relating to" are not included as the first words in the title of an application because a patent application is, by nature, a new idea or improvement.

The title may be truncated if it consists of more than 4 lines of 70 characters each (letters and spaces combined).

The inventor information may be truncated if the family name consists of more than 25 characters (letters and spaces combined) and if the given name consists of more than 25 characters (letters and spaces combined). The inventor's residence allows for up to 40 characters (letters and spaces combined).

The docket number allows a maximum of 12 characters.

If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."

Customer Address may have been modified to conform to U.S. Postal rules.

Please direct correction, including a copy of your Filing Receipt, to:

Assistant Commissioner for Patents  
Office of Initial Patent Examination  
Customer Service Center  
Washington, DC 20231

AUG 03 2001

**TRANSMITTAL LETTER**  
(General - Patent Pending)

Docket No.  
44041.010400

In Re Application of: Cochrum *et al.*

Serial No.  
09/438,872

Filing Date  
November 12, 1999

Examiner  
Sandra Saucier

Group Art Unit  
1651

Title: Hemostatic Polymer Useful for Rapid Blood Coagulation and Hemostasis

**RECEIVED**

AUG 17 2001

TECH CENTER 1600/2900


TO THE ASSISTANT COMMISSIONER FOR PATENTS:

Transmitted herewith is:

(a) Petition for Extension of Time under 37 CFR 1.136(a) in duplicate; (b) Amendment Transmittal Letter in duplicate; (c) Amendment and Response to Office Action; (d) Change of Attorney or Agent's Address in Application; (e) Request for Corrected Filing Receipt; (f) Return Receipt Postcard and (g) the present Transmittal Letter.

in the above identified application.


- ☐ No additional fee is required.
- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. ~~501-5011~~ as described below. A duplicate copy of this sheet is enclosed.
- ☒ Charge the amount of ~~\$654.00~~
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

  
Signature

Eugene C. Rzucidlo  
Attorney Registration No. 31, 900  
Greenberg Traurig, LLP  
Twenty-Second Floor  
885 Third Avenue  
New York, New York 10022

Dated: August 1, 2001

I certify that this document and fee is being deposited on 08/01/01 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.



Signature of Person Mailing Correspondence

A. Scheffer

Typed or Printed Name of Person Mailing Correspondence

CC:

## AMENDMENT TRANSMITTAL LETTER (Small Entity)

Applicant(s): C. Chiriac

Docket No.

44041.010400

Serial No.

09/438,872

Filing Date

November 12, 1999

Examiner

Sandra Saucier

Group Art Unit

1651

Invention: Hemostatic Reagent Useful for Rapid Blood Coagulation and Hemostasis

RECEIVED

AUG 17 2001

TO THE ASSISTANT COMMISSIONER FOR PATENTS:

TECH CENTER 1600/2900

Transmitted herewith is an amendment in the above-identified application.

- ☒ Small Entity status of this application has been established under 37 CFR 1.27 by a verified statement previously submitted.
- ☐ A verified statement to establish Small Entity status under 37 FR 1.27 is enclosed.

The fee has been calculated and is transmitted as shown below.

## CLAIMS AS AMENDED

	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	45 -	44 =	1 x	\$9.00	\$9.00
INDEP. CLAIMS	10 -	5 =	5 x	\$40.00	\$200.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT					\$209.00

- ☐ No additional fee is required for amendment.
- ☒ Please charge Deposit Account No. 501-561 in the amount of \$209.00.  
A duplicate copy of this sheet is enclosed.
- ☐ A check in the amount of \_\_\_\_\_ to cover the filing fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 501-561.  
A duplicate copy of this sheet is enclosed.
- ☒ Any additional filing fees required under 37 C.F.R. 1.16.
- ☒ Any patent application processing fees under 37 CFR 1.17.

Dated: August 1, 2001

Eugene C. Rzucidlo  
Attorney Registration No. 31,900  
Greenberg Traurig, LLP  
Twenty-Second Floor  
885 Third Avenue  
New York, New York 10022

I certify that this document and fee is being deposited on 08/11/01 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

A. Scheffer

Signature of Person Mailing Correspondence

A. Scheffer

Typed or Printed Name of Person Mailing Correspondence


CC:

#12

**Change Of Attorney Or Agent's Address In Application**  
(37 CFR 1.8(a))

Docket No.  
**44041.010400**

In Re Application Of: *Cochrum et al.*



Serial No.  
**09/438,872**

Filing Date  
**November 12, 1999**

Examiner  
**Sandra Saucier**

Group Art Unit  
**1651**

Invention: **Hemostatic Polymer Useful for Rapid Blood Coagulation and Hemostasis**


TO THE ASSISTANT COMMISSIONER FOR PATENTS

Please send all correspondence for this application to:

**Eugene C. Rzucidlo, Esq.**  
**Attorney Registration No. 31,900**  
**Greenberg Traurig, LLP**  
**885 Third Avenue**  
**Twenty-Second Floor**  
**New York, New York 10022**

Please direct all telephone calls to:

**Eugene C. Rzucidlo, Esq.**  
**Attorney Registration No. 31,900**  
**Greenberg Traurig, LLP**  
**885 Third Avenue**  
**Twenty-Second Floor**  
**New York, New York 10022**  
**Telephone: 212-801-9200**  
**Fax: 212-688-2449**

  
\_\_\_\_\_  
*Signature of Attorney or Agent of Record*

Dated: **August 1, 2001**

**Eugene C. Rzucidlo, Esq.**  
**Attorney Registration No. 31,900**  
**Greenberg Traurig, LLP**  
**885 Third Avenue**  
**Twenty-Second Floor**  
**New York, New York 10022**

*Registration Number & Address of Attorney or Agent of Record*

I certify that this document is being deposited on  
**08/01/01** with the U.S. Postal Service as first  
class mail under 37 C.F.R. 1.8 and is addressed to the  
Assistant Commissioner for Patents, Washington, D.C.  
20231.

  
\_\_\_\_\_  
*Signature of Person Mailing Correspondence*

**A. Scheffer**

*Typed or Printed Name of Person Mailing Correspondence*

**CERTIFICATE OF MAILING BY FIRST CLASS MAIL (37 CFR 1.8)**Applicant(s): Cochran et al.

Docket No.

44041.010400

Serial No.

09/438,872

Filing Date

November 12, 1999

Examiner

Sandra Saucier

Group Art Unit

1651

Invention: Hemostatic Polymer Useful for Rapid Blood Coagulation and Hemostasis

I hereby certify that this Response to Office Action, Petition for Extension of Time, and related items  
(Identify type of correspondence)

is being deposited with the United States Postal Service as first class mail in an envelope addressed to: The

Assistant Commissioner for Patents, Washington, D.C. 20231 on

August 1, 2001

(Date)

A. Scheffer

(Typed or Printed Name of Person Mailing Correspondence)

A. Scheffer

(Signature of Person Mailing Correspondence)

**Note: Each paper must have its own certificate of mailing.**